Sixty-five advanced melanoma patients were identified, of whom 46 met inclusion criteria and were included in this study. Increased densities (P = 0.04) and proportions (P = 0.02) of CD8+ T cells expressing CD103+ were associated with complete response (CR) to pembrolizumab. Improved survival was associated with increased proportions of CD8+ cells expressing CD103 (P = 0.0085) as well as decreased density of periplakin+ cells (P = 0.012) and periplakin+SOX10+ cells (P = 0.0012).